Physician profile
Amanda Bernard
NPI 1922590348
$7,650.61
in general payments reported to CMS, 2019-2025
22 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,780 · 2022: $1,616 · 2023: $1,363 · 2024: $1,464 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,179.28 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,118.15 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,580.23 | 2021-2025 | |
| Lundbeck LLC | $583.37 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $454.37 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $393.61 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $366.94 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $355.19 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $324.32 | 2022-2024 | Azstarys |
| Alkermes, INC. | $306.15 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $224.19 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.21 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $174.43 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $132.42 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $106.93 | 2021-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $91.64 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $67.06 | 2024-2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $63.24 | 2022-2024 | Jornay Pm |
| Novo Nordisk INC | $35.48 | 2024 | |
| Janssen Biotech, INC. | $22.47 | 2024 | Spravato |
| Almatica Pharma LLC | $16.74 | 2022 | |
| Alfasigma USA, INC. | $15.79 | 2021 | |
| Bausch Health US, LLC | $13.68 | 2024 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.